<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135356</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-131</org_study_id>
    <nct_id>NCT00135356</nct_id>
  </id_info>
  <brief_title>Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome</brief_title>
  <official_title>A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if human immunodeficiency virus
      (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral
      treatment (HAART) regimen have better changes in fat distribution after switching to
      atazanavir-ritonavir than those remaining on their current protease inhibitor boosted HAART
      regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Mean changes from Baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values. (Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by DEXA at Week 96</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values.(Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Visceral Adipose Tissue (VAT) Area by Computed Tomography (CT) Scans and in Trunk Fat by DEXA.</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>The mean percent change from baseline in physical signs of lipohypertrophy, as assessed objectively by changes in visceral adipose tissue (VAT) area (cm2) by computed tomography (CT) scans and by changes in trunk fat (kg) by DEXA. Clinical improvement is associated with a decrease in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Peripheral Adipose Tissue (Limb Fat) by DEXA and by Changes in Subcutaneous Adipose Tissue (SAT) Area by CT Scans</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>The mean percent change from baseline in physical signs of lipoatrophy, as assessed objectively by changes in peripheral adipose tissue (ie, limb fat (kg) by DEXA and in subcutaneous adipose tissue (SAT) area by CT scans. Clinical improvement is associated with stable values, or an increase in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Total Body Fat by DEXA and in Total Adipose Tissue (TAT) Area by CT Scans</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>The mean percent change from baseline in total body fat by DEXA and in total adipose tissue (TAT) area by CT scans. Total body fat and TAT are both associated many factors (trunk fat + limb fat + other [weight, etc]), and thus clinical improvement cannot be predicted based solely an increase or decrease of these values. (Baseline values can be found in the Baseline Characteristics section.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Changes From Baseline in Fasting Lipids</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>Mean percent changes from baseline in fasting total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and non-HDL cholesterol, triglycerides, and apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Fasting Glucose at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Fasting Insulin at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>HOMA-IR is an index used in evaluation of obese patients at risk for type 2 diabetes which requires fasting glucose and insulin concentrations. It is a mathematical model based on the theory of a negative feedback loop between the liver and β-cells that regulates both fasting glucose and insulin concentrations and can be used to estimate pancreatic β-cell function and degree of insulin resistance. HOMA-IR normal values are between 2 and 2.5. HOMA-IR ≥ 2.5 indicates insulin-resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Body Weight at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Waist Circumference at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Body Mass Index at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in Waist-to-Hip Ratio at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>Mean changes from baseline in proportion of waist to hip measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation</measure>
    <time_frame>Through Week 96 of study therapy</time_frame>
    <description>Percentage of Participants with AEs, Serious AEs (SAEs), Deaths, and AEs leading to discontinuation. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Liver Function Tests</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>Percentage of participants with Abnormal Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Total Bilirubin (TBILI) measurements. Values for liver tests are graded using the modified World Health Organization (WHO) criteria. Grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life threatening or disabling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation</measure>
    <time_frame>Through Week 96</time_frame>
    <description>Percentage of Participants with AEs leading to discontinuation of study therapy. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. All events listed in this table were SAEs, except for renal impairment and hypertriglycerideamia, which were an AEs (and did not meet the 5 percent threshold reported in Adverse Event module of this record).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Cumulative Proportion of Participants Without Virologic Rebound (HIV RNA ≥400 c/mL) at Timepoints up to Week 96 in Treated Participants With HIV RNA &lt;400 c/mL at Baseline</measure>
    <time_frame>Weeks 8-12, Weeks 20-24, Weeks 32-36, Weeks 44-48, Weeks 56-60, Weeks 68-72, Weeks 80-84, Weeks 92-96</time_frame>
    <description>Virologic rebound was measured from the first dose of study therapy to the first of the 2 consecutive measurements ≥400 c/mL. Time to virologic rebound was analyzed using life tables. Measured Values show the Kaplan-Meier cumulative proportion of participants without virologic rebound up to the end of the respective interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4 Count</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>Mean change from baseline in CD4 count among treated subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <arm_group>
    <arm_group_label>Switch arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)</intervention_name>
    <description>Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks</description>
    <arm_group_label>Switch arm</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)</intervention_name>
    <description>Protease inhibitor [PI] combination + 2 NRTIs</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected on HAART regimen containing 2 NRTI and boosted PI for at least 12 weeks
             prior to screening. Subjects may not have experienced virological failure to more than
             one prior PI-containing regimen. Must be able to swallow tablets

          -  Viral load &lt;400 c/mL at screening and stable for at least 6 months

          -  Signs of fat redistribution and lipohypertrophy (abdominal) Waist to Hip Ratio &gt;0.90
             and Waist Circumference &gt;88.2 cm for men and Waist Circumference &gt;75.3 for women

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  New HIV-related opportunistic infections

          -  Active alcohol or substance use

          -  Grade 4 lab toxicity

          -  History of taking atazanavir (ATV)

          -  Prohibited therapies, including non-nucleoside reverse transcriptase inhibitors
             (NNRTI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lagny-sur-Marne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 02</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 03</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt/ Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Elche (Alicante)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guipuzcoa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <results_first_submitted>December 15, 2009</results_first_submitted>
  <results_first_submitted_qc>April 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2010</results_first_posted>
  <last_update_submitted>April 20, 2010</last_update_submitted>
  <last_update_submitted_qc>April 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 219 participants were enrolled and 18 were never randomized (1 poor/noncompliance; 10 no longer met study criteria; 5 withdrew consent). 201 participants were randomized; however, 1 participant was never treated and is not included in the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ATV/RTV Switch Arm</title>
          <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
        </group>
        <group group_id="P2">
          <title>PI/RTV Control Arm</title>
          <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131">Number randomized and treated</participants>
                <participants group_id="P2" count="69">Number randomized and treated(1 randomized and never treated subject not included in this number.)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Prior to Week 96 Visit</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued on or After Week 96 Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery for abdominal fat</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in antiviral regimen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ATV/RTV Switch Arm</title>
          <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
        </group>
        <group group_id="B2">
          <title>PI/RTV Control Arm</title>
          <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="23" upper_limit="79"/>
                    <measurement group_id="B2" value="42" lower_limit="26" upper_limit="65"/>
                    <measurement group_id="B3" value="43" lower_limit="23" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino/Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster of Differentiation 4 (CD4) Distribution</title>
          <description>CD4=a protein marker on the surface of certain types of T lymphocytes and other cells; HIV binds to CD4 receptors to enter host cells.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50 to &lt;100 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 to &lt;200 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>200 to &lt;350 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>350 to &lt;500 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥500 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <description>7 participants in ATV/RTV arm and 3 participants in PI/RTV arm were missing this baseline measurement.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;100 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96" lower_limit="83.0" upper_limit="99.0"/>
                    <measurement group_id="B2" value="49" lower_limit="82.0" upper_limit="100.0"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg/dL to &lt;126 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=126 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Lipids</title>
          <description>Triglycerides, non-high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, total cholesterol, and HDL cholesterol. Values for all baseline fasting lipid measurements were missing for 8 participants in the ATV/RTV arm. Values for baseline fasting LDL cholesterol were missing for 8 participants in the PI/RTV arm; values for all other baseline lipid measurements were missing for 7 participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Triglycerides &lt;150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="41" upper_limit="54"/>
                    <measurement group_id="B2" value="14" lower_limit="35" upper_limit="53"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides 150 mg/dL to &lt;200 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="139" upper_limit="198"/>
                    <measurement group_id="B2" value="9" lower_limit="126" upper_limit="192"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides 200 mg/dL to &lt;500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="90" upper_limit="143"/>
                    <measurement group_id="B2" value="27" lower_limit="84" upper_limit="125"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides &gt;=500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="151" upper_limit="326"/>
                    <measurement group_id="B2" value="12" lower_limit="154" upper_limit="425"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL Cholesterol &lt;130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="80" upper_limit="111"/>
                    <measurement group_id="B2" value="16" lower_limit="78" upper_limit="111"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL Cholesterol 130 mg/dL to &lt;160 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL Cholesterol 160 mg/dL to &lt;190 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL Cholesterol 190 mg/dL to &lt;220 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL Cholesterol &gt;=220 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol &lt;100 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol 100 mg/dL to &lt;130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol 130 mg/dL to &lt;160 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol 160 mg/dL to &lt;190 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol &gt;=190 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol &lt;200 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol 200 mg/dL to 240 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol 240 mg/dL to 300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol &gt;=300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol &lt;40 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol 40 mg/dL to &lt;60 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol &gt;=60 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Immunodeficiency Virus Ribonucleic Acid (HIV RNA) Distribution</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to &lt;400 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 to &lt;1000 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1000 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adipose Tissue at Baseline</title>
          <description>Visceral, subcutaneous, and total adipose tissue (VAT, SAT, and TAT) as assessed by computed tomography (CT). Values for all 3 measurements were missing for 20 participants in the ATV/RTV arm (n=111). Values for all 3 measurements were missing for 10 participants in the PI/RTV arm (n=59).</description>
          <units>cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>VAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131.9" lower_limit="93.8" upper_limit="185.8"/>
                    <measurement group_id="B2" value="128.1" lower_limit="95.8" upper_limit="193.7"/>
                    <measurement group_id="B3" value="129.4" lower_limit="94.3" upper_limit="186.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209.5" lower_limit="123.6" upper_limit="300.7"/>
                    <measurement group_id="B2" value="183.9" lower_limit="151.4" upper_limit="282.4"/>
                    <measurement group_id="B3" value="193.6" lower_limit="140.3" upper_limit="289.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356.2" lower_limit="263.9" upper_limit="446.3"/>
                    <measurement group_id="B2" value="328.6" lower_limit="287.3" upper_limit="457.8"/>
                    <measurement group_id="B3" value="352.0" lower_limit="268.5" upper_limit="453.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>131 participants in ATV/RTV arm and 67 participants in PI/RTV arm had this baseline measurement.</description>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" lower_limit="24.1" upper_limit="28.5"/>
                    <measurement group_id="B2" value="25.7" lower_limit="24.2" upper_limit="28.8"/>
                    <measurement group_id="B3" value="25.9" lower_limit="24.2" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="69" upper_limit="83"/>
                    <measurement group_id="B2" value="77" lower_limit="69" upper_limit="87"/>
                    <measurement group_id="B3" value="76" lower_limit="69" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Cell Count</title>
          <description>CD4 cell=a type of white blood cell that bears the CD4 surface receptor and helps coordinate a range of immune system activities.</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="470" lower_limit="90" upper_limit="1919"/>
                    <measurement group_id="B2" value="437" lower_limit="100" upper_limit="1078"/>
                    <measurement group_id="B3" value="459" lower_limit="90" upper_limit="1919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trunk Fat, Limb Fat, Total Body Fat</title>
          <description>Values for all 3 baseline fat measurements were missing for 14 participants in the ATV/RTV arm (n=117). Values for baseline trunk fat measurements were missing for 10 participants in the PI/RTV arm (n=59); values for baseline limb fat and total body fat measurements were missing for 13 participants in the PI/RTV arm (n=56).</description>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Trunk Fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" lower_limit="8.6" upper_limit="15.3"/>
                    <measurement group_id="B2" value="10.9" lower_limit="8.8" upper_limit="13.8"/>
                    <measurement group_id="B3" value="11.4" lower_limit="8.7" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limb Fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" lower_limit="4.6" upper_limit="10.4"/>
                    <measurement group_id="B2" value="6.7" lower_limit="4.6" upper_limit="9.4"/>
                    <measurement group_id="B3" value="7.0" lower_limit="4.6" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Body Fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" lower_limit="14.1" upper_limit="26.0"/>
                    <measurement group_id="B2" value="18.7" lower_limit="15.6" upper_limit="22.4"/>
                    <measurement group_id="B3" value="19.8" lower_limit="14.8" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trunk-to-Limb Fat Ratio</title>
          <description>117 participants in ATV/RTV arm and 56 participants in PI/RTV arm had this measure at baseline.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.59" lower_limit="1.27" upper_limit="2.04"/>
                    <measurement group_id="B2" value="1.73" lower_limit="1.17" upper_limit="2.15"/>
                    <measurement group_id="B3" value="1.62" lower_limit="1.23" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94" lower_limit="90" upper_limit="103"/>
                    <measurement group_id="B2" value="95" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="B3" value="94" lower_limit="90" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist-to-Hip Ratio</title>
          <description>131 participants in ATV/RTV arm and 68 participants in PI/RTV arm had this baseline measurement.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.99" lower_limit="0.95" upper_limit="1.03"/>
                    <measurement group_id="B2" value="0.97" lower_limit="0.94" upper_limit="1.02"/>
                    <measurement group_id="B3" value="0.99" lower_limit="0.95" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48</title>
        <description>Mean changes from Baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values. (Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Treated participants. Observed case (OC) analysis: n=participants with fat measurement at baseline and at the analysis timepoint. Last observation carried forward (LOCF): n=participants with fat measurement at baseline and at or before the analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48</title>
          <description>Mean changes from Baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values. (Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
          <population>Treated participants. Observed case (OC) analysis: n=participants with fat measurement at baseline and at the analysis timepoint. Last observation carried forward (LOCF): n=participants with fat measurement at baseline and at or before the analysis timepoint.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LOCF Population (n=112; n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.027"/>
                    <measurement group_id="O2" value="-0.02" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCPopulation (n=105; n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.029"/>
                    <measurement group_id="O2" value="-0.01" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>P-value not adjusted for multiple testing. 2-sided 95% CI</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by DEXA at Week 96</title>
        <description>Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values.(Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Observed case (OC) analysis: n=participants with fat measurement at baseline and at the analysis timepoint. Last observation carried forward (LOCF): n=participants with fat measurement at baseline and at or before the analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trunk-to-limb Fat Ratio as Measured by DEXA at Week 96</title>
          <description>Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values.(Baseline trunk-to-limb fat ratio values can be found in the Baseline Characteristics section.)</description>
          <population>Observed case (OC) analysis: n=participants with fat measurement at baseline and at the analysis timepoint. Last observation carried forward (LOCF): n=participants with fat measurement at baseline and at or before the analysis timepoint.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LOCF Population (n=112; n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.035"/>
                    <measurement group_id="O2" value="0.02" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OC Population (n=94; n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.041"/>
                    <measurement group_id="O2" value="0.05" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Visceral Adipose Tissue (VAT) Area by Computed Tomography (CT) Scans and in Trunk Fat by DEXA.</title>
        <description>The mean percent change from baseline in physical signs of lipohypertrophy, as assessed objectively by changes in visceral adipose tissue (VAT) area (cm2) by computed tomography (CT) scans and by changes in trunk fat (kg) by DEXA. Clinical improvement is associated with a decrease in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>VAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before the analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Visceral Adipose Tissue (VAT) Area by Computed Tomography (CT) Scans and in Trunk Fat by DEXA.</title>
          <description>The mean percent change from baseline in physical signs of lipohypertrophy, as assessed objectively by changes in visceral adipose tissue (VAT) area (cm2) by computed tomography (CT) scans and by changes in trunk fat (kg) by DEXA. Clinical improvement is associated with a decrease in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
          <population>VAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before the analysis timepoint.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 VAT (n=98; n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="-13.8" upper_limit="25.7"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-10.8" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 VAT (n=101; n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="-11.7" upper_limit="26.5"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-12.4" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Trunk Fat (n=112; n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-5.8" upper_limit="12.4"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-10.0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 Trunk Fat (n=112; n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-6.7" upper_limit="14.3"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-12.9" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48 VAT LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Mean</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>15.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAT, Week 96 LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Mean</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48 Trunk Fat LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96 Trunk Fat LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>12.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Peripheral Adipose Tissue (Limb Fat) by DEXA and by Changes in Subcutaneous Adipose Tissue (SAT) Area by CT Scans</title>
        <description>The mean percent change from baseline in physical signs of lipoatrophy, as assessed objectively by changes in peripheral adipose tissue (ie, limb fat (kg) by DEXA and in subcutaneous adipose tissue (SAT) area by CT scans. Clinical improvement is associated with stable values, or an increase in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>SAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Peripheral Adipose Tissue (Limb Fat) by DEXA and by Changes in Subcutaneous Adipose Tissue (SAT) Area by CT Scans</title>
          <description>The mean percent change from baseline in physical signs of lipoatrophy, as assessed objectively by changes in peripheral adipose tissue (ie, limb fat (kg) by DEXA and in subcutaneous adipose tissue (SAT) area by CT scans. Clinical improvement is associated with stable values, or an increase in values. (Baseline values can be found in the Baseline Characteristics section.)</description>
          <population>SAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before analysis timepoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 SAT (n=108; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-11.6" upper_limit="8.7"/>
                    <measurement group_id="O2" value="-5.9" lower_limit="-14.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 SAT (n=111; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-15.7" upper_limit="8.7"/>
                    <measurement group_id="O2" value="-9.7" lower_limit="-21.6" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Limb Fat (n=112; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-7.4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-15.5" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Limb Fat (n=112; n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-11.3" upper_limit="12.2"/>
                    <measurement group_id="O2" value="-6.1" lower_limit="-19.8" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SAT, Week 48, LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96 SAT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Mean</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48, Limb Fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96, Limb Fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Total Body Fat by DEXA and in Total Adipose Tissue (TAT) Area by CT Scans</title>
        <description>The mean percent change from baseline in total body fat by DEXA and in total adipose tissue (TAT) area by CT scans. Total body fat and TAT are both associated many factors (trunk fat + limb fat + other [weight, etc]), and thus clinical improvement cannot be predicted based solely an increase or decrease of these values. (Baseline values can be found in the Baseline Characteristics section.)</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>TAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before the analysis timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Total Body Fat by DEXA and in Total Adipose Tissue (TAT) Area by CT Scans</title>
          <description>The mean percent change from baseline in total body fat by DEXA and in total adipose tissue (TAT) area by CT scans. Total body fat and TAT are both associated many factors (trunk fat + limb fat + other [weight, etc]), and thus clinical improvement cannot be predicted based solely an increase or decrease of these values. (Baseline values can be found in the Baseline Characteristics section.)</description>
          <population>TAT analysis population=treated subjects with adipose tissue pairs (LOCF); trunk fat analysis population=treated subjects with fat pairs (LOCF); n=number of subjects with measurement at baseline and at or before the analysis timepoint</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 TAT (n=108; n= 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-9.0" upper_limit="10.8"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-12.7" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 TAT (n=111; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-9.2" upper_limit="12.7"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-16.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Total Body Fat (n=105; n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-5.4" upper_limit="11.5"/>
                    <measurement group_id="O2" value="-3.7" lower_limit="-10.9" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 Total Body Fat (n=94; n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-9.5" upper_limit="11.8"/>
                    <measurement group_id="O2" value="-7.4" lower_limit="-16.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48 TAT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>DIfference in Means</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96 TAT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>DIfference in Means</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48 Total Body Fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0385</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96 Total Body Fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>P-value not adjusted for multiple testing, 2-sided 95% CI.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Means</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Changes From Baseline in Fasting Lipids</title>
        <description>Mean percent changes from baseline in fasting total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and non-HDL cholesterol, triglycerides, and apolipoprotein B</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Treated Subjects (LOCF). n=56 for LDL cholesterol in the PI/RTV arm at both timepoints</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Changes From Baseline in Fasting Lipids</title>
          <description>Mean percent changes from baseline in fasting total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and non-HDL cholesterol, triglycerides, and apolipoprotein B</description>
          <population>Treated Subjects (LOCF). n=56 for LDL cholesterol in the PI/RTV arm at both timepoints</population>
          <units>Percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 - Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0"/>
                    <measurement group_id="O2" value="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2"/>
                    <measurement group_id="O2" value="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - Non-HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8"/>
                    <measurement group_id="O2" value="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8"/>
                    <measurement group_id="O2" value="-11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - Apolipoprotein B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5"/>
                    <measurement group_id="O2" value="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8"/>
                    <measurement group_id="O2" value="-4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - Non-HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0"/>
                    <measurement group_id="O2" value="-12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - Apolipoprotein B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Fasting Glucose at Week 48 and Week 96</title>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Fasting Glucose at Week 48 and Week 96</title>
          <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=124; n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.60"/>
                    <measurement group_id="O2" value="-3.3" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=124; n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.82"/>
                    <measurement group_id="O2" value="3.0" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Fasting Insulin at Week 48 and Week 96</title>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Fasting Insulin at Week 48 and Week 96</title>
          <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
          <units>microunits per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=124; n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="1.04"/>
                    <measurement group_id="O2" value="21.8" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=124; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.46"/>
                    <measurement group_id="O2" value="-4.1" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=124; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.20"/>
                    <measurement group_id="O2" value="0.3" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR is an index used in evaluation of obese patients at risk for type 2 diabetes which requires fasting glucose and insulin concentrations. It is a mathematical model based on the theory of a negative feedback loop between the liver and β-cells that regulates both fasting glucose and insulin concentrations and can be used to estimate pancreatic β-cell function and degree of insulin resistance. HOMA-IR normal values are between 2 and 2.5. HOMA-IR ≥ 2.5 indicates insulin-resistance.</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR is an index used in evaluation of obese patients at risk for type 2 diabetes which requires fasting glucose and insulin concentrations. It is a mathematical model based on the theory of a negative feedback loop between the liver and β-cells that regulates both fasting glucose and insulin concentrations and can be used to estimate pancreatic β-cell function and degree of insulin resistance. HOMA-IR normal values are between 2 and 2.5. HOMA-IR ≥ 2.5 indicates insulin-resistance.</description>
          <population>Treated participants (LOCF); n=number of participants with baseline value at or before analysis timepoint.</population>
          <units>mg/dL x uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=115; n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.309"/>
                    <measurement group_id="O2" value="5.43" spread="1.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=115; n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.589"/>
                    <measurement group_id="O2" value="-1.73" spread="1.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=115; n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.500"/>
                    <measurement group_id="O2" value="1.00" spread="1.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Body Weight at Week 48 and Week 96</title>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Body Weight at Week 48 and Week 96</title>
          <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=130; n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.3"/>
                    <measurement group_id="O2" value="-1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=130; n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.4"/>
                    <measurement group_id="O2" value="-1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Waist Circumference at Week 48 and Week 96</title>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Waist Circumference at Week 48 and Week 96</title>
          <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=123; n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.5"/>
                    <measurement group_id="O2" value="-1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=124; n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.6"/>
                    <measurement group_id="O2" value="-1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Body Mass Index at Week 48 and Week 96</title>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Body Mass Index at Week 48 and Week 96</title>
          <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=130; n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.12"/>
                    <measurement group_id="O2" value="-0.2" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=130; n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.13"/>
                    <measurement group_id="O2" value="-0.5" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in Waist-to-Hip Ratio at Week 48 and Week 96</title>
        <description>Mean changes from baseline in proportion of waist to hip measurements.</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Waist-to-Hip Ratio at Week 48 and Week 96</title>
          <description>Mean changes from baseline in proportion of waist to hip measurements.</description>
          <population>LOCF; n=number of participants with baseline value and value at or before analysis timepoint</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=123; n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.005"/>
                    <measurement group_id="O2" value="-0.01" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=124; n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.006"/>
                    <measurement group_id="O2" value="-0.01" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation</title>
        <description>Percentage of Participants with AEs, Serious AEs (SAEs), Deaths, and AEs leading to discontinuation. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Through Week 96 of study therapy</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation</title>
          <description>Percentage of Participants with AEs, Serious AEs (SAEs), Deaths, and AEs leading to discontinuation. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>Treated participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs (all grades) through Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal Liver Function Tests</title>
        <description>Percentage of participants with Abnormal Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Total Bilirubin (TBILI) measurements. Values for liver tests are graded using the modified World Health Organization (WHO) criteria. Grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life threatening or disabling.</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Liver Function Tests</title>
          <description>Percentage of participants with Abnormal Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Total Bilirubin (TBILI) measurements. Values for liver tests are graded using the modified World Health Organization (WHO) criteria. Grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life threatening or disabling.</description>
          <population>All treated participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 48 ALT Grades 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 ALT Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 ALT Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 ALT Grades 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 ALT Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 ALT Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 AST Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 AST Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 AST Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 AST Grades 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 AST Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 AST Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 TBILI Grades 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 TBILI Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48 TBILI Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 TBILI Grades 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 TBILI Grades 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 96 TBILI Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation</title>
        <description>Percentage of Participants with AEs leading to discontinuation of study therapy. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. All events listed in this table were SAEs, except for renal impairment and hypertriglycerideamia, which were an AEs (and did not meet the 5 percent threshold reported in Adverse Event module of this record).</description>
        <time_frame>Through Week 96</time_frame>
        <population>Treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation</title>
          <description>Percentage of Participants with AEs leading to discontinuation of study therapy. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. All events listed in this table were SAEs, except for renal impairment and hypertriglycerideamia, which were an AEs (and did not meet the 5 percent threshold reported in Adverse Event module of this record).</description>
          <population>Treated subjects</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse experience leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug abuse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stevens-Johnson syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertriglyceridemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Cumulative Proportion of Participants Without Virologic Rebound (HIV RNA ≥400 c/mL) at Timepoints up to Week 96 in Treated Participants With HIV RNA &lt;400 c/mL at Baseline</title>
        <description>Virologic rebound was measured from the first dose of study therapy to the first of the 2 consecutive measurements ≥400 c/mL. Time to virologic rebound was analyzed using life tables. Measured Values show the Kaplan-Meier cumulative proportion of participants without virologic rebound up to the end of the respective interval.</description>
        <time_frame>Weeks 8-12, Weeks 20-24, Weeks 32-36, Weeks 44-48, Weeks 56-60, Weeks 68-72, Weeks 80-84, Weeks 92-96</time_frame>
        <population>Treated subjects with HIV RNA &lt;400 c/mL at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Cumulative Proportion of Participants Without Virologic Rebound (HIV RNA ≥400 c/mL) at Timepoints up to Week 96 in Treated Participants With HIV RNA &lt;400 c/mL at Baseline</title>
          <description>Virologic rebound was measured from the first dose of study therapy to the first of the 2 consecutive measurements ≥400 c/mL. Time to virologic rebound was analyzed using life tables. Measured Values show the Kaplan-Meier cumulative proportion of participants without virologic rebound up to the end of the respective interval.</description>
          <population>Treated subjects with HIV RNA &lt;400 c/mL at baseline.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>By Weeks 8-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9837" lower_limit="0.31" upper_limit="22.68"/>
                    <measurement group_id="O2" value="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 20-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9837" lower_limit="0.30" upper_limit="3.72"/>
                    <measurement group_id="O2" value="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 32-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9753"/>
                    <measurement group_id="O2" value="0.9841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 44-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9669"/>
                    <measurement group_id="O2" value="0.9841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 56-60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9585"/>
                    <measurement group_id="O2" value="0.9841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 68-72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9585"/>
                    <measurement group_id="O2" value="0.9841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 80-84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9585"/>
                    <measurement group_id="O2" value="0.9674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>By Weeks 92-96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9585"/>
                    <measurement group_id="O2" value="0.9309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>3.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4 Count</title>
        <description>Mean change from baseline in CD4 count among treated subjects</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Observed Cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>ATV/RTV Switch Arm</title>
            <description>Participants switching their current treatment with a ritonavir (RTV)-boosted protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) regimen to atazanavir (ATV)/RTV (ATV: 2 x 150 mg capsules once daily (QD) / RTV: 1 x 100 mg capsule QD) while continuing their background nucleoside reverse transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>PI/RTV Control Arm</title>
            <description>Participants continued on their current treatment with an RTV-boosted, PI-containing HAART regimen while continuing their background NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4 Count</title>
          <description>Mean change from baseline in CD4 count among treated subjects</description>
          <population>Observed Cases (OC)</population>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 (n=114; n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="13.1"/>
                    <measurement group_id="O2" value="44" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=96; n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="16.9"/>
                    <measurement group_id="O2" value="82" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ATV/RTV Switch Arm</title>
        </group>
        <group group_id="E2">
          <title>PI/RTV Control Arm</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>NEUROSYPHILIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>STEVENS-JOHNSON SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

